全球平均壽命愈來愈長，人口數愈來愈多，製藥產業日趨重要，市場不斷地成長。而美國及日本銷售量最高的製藥企業輝瑞與武田，兩家大型製藥企業目前共同面臨到最大的危機就是旗下的暢銷藥品專利即將到期，研發新藥到上市所需耗費的時間與資金龐大，因此，大型的製藥企業普遍在研發的同時採用併購或與其他廠商聯盟合夥的策略。而兩家企業國際化的程度，是造成規模差距的主要原因。新興國家可透過投入研發與建立監管制度、幫助國際大廠代工及與其聯盟、轉型另闢營收與搶占新興市場來強化國內的製藥產業。本研究之目的在於藉由分析美國及日本銷售量最高的製藥企業，探討成功的大型製藥企業之經營模式是否有其相同或相異之處，並反觀台灣目前的製藥廠商，建議其可採取的行動或策略，希望透過本研究對於製藥先進國家大型製藥企業的分析，能夠為台灣發展中的製藥產業帶來一些貢獻。

Pharmaceutical industry becomes more and more important because of the global average life and populations are getting growth continually. However, the top selling pharmaceutical companies in American and Japanese, Pfizer and Takeda, both face the biggest problem about off-patent of their blockbusters which would affect their sales seriously. They should increase their drugs and product lines to solve it. But research and developing new drugs need lots of time and cost, so large pharmaceutical companies especially Pfizer use merger and acquisition at the same time to get new blockbusters. And Takeda also uses alliance to cooperate with other authorities. The biggest difference between the two companies is the degree of internationalization. The purpose of this thesis is analyzing the top selling American and Japanese pharmaceutical companies through Hamel’s business model, and discusses the differences between the two companies. And then giving some advises to Taiwan pharmaceutical industry to realize what strategy or action can be taken. Pharmaceutical industry becomes more and more important because of the global average life and populations are getting growth continually. Hoping this research about analyzing pharmaceutical companies of advanced countries can bring some contributions developed pharmaceutical industry of Taiwan.